Quick Answer
ImmunityBio, Inc. reported Cash and Equivalents of $88.33 million for fiscal year 2025.
ImmunityBio, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $88.33M | -38.4% |
| 2024 | $143.43M | -46.0% |
| 2023 | $265.45M | +153.7% |
| 2022 | $104.64M | -42.2% |
| 2021 | $181.10M | +418.7% |
| 2020 | $34.91M | -53.9% |
| 2019 | $75.80M | +350.6% |
| 2018 | $16.82M | -29.5% |
| 2017 | $23.87M | +195.3% |
| 2016 | $8.08M | -95.4% |
| 2015 | $175.91M | +197.6% |
| 2014 | $59.10M | +16786.9% |
| 2013 | $350.0K | +201.7% |
| 2012 | $116.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $60.24M | -46.2% | -56.2% |
| June 30, 2025 | $137.66M | +5.8% | +126.9% |
| March 31, 2025 | $60.66M | -54.4% | -57.7% |
| December 31, 2024 | $143.43M | -46.0% | +28.1% |
| September 30, 2024 | $111.97M | -37.1% | -13.9% |
| June 30, 2024 | $130.10M | +199.0% | -2.2% |
| March 31, 2024 | $133.03M | +50.4% | -49.9% |
| December 31, 2023 | $265.45M | +153.7% | +49.2% |
- ImmunityBio, Inc. showed a decrease of -38.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, ImmunityBio, Inc.’s cash and equivalents has grown by 76050.0% (from $116.0 thousand to $88.33 million).
- The most recent figure is from ImmunityBio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: